Viatris Inc. has announced the sale of its equity stake in Biocon Biologics Limited for $815 million, consisting of $400 million in cash and $415 million in equity shares, to regain access to the biosimilars market globally.

About the Target

Viatris Inc. is a global healthcare company that combines the advantages of generics and brand-name pharmaceuticals to provide a comprehensive approach to healthcare. Headquartered in the United States, Viatris operates through global centers located in Pittsburgh, Shanghai, and Hyderabad, India. With a mission to empower individuals to lead healthier lives at every stage, the company serves around one billion patients worldwide annually, addressing a myriad of health conditions from acute to chronic diseases.

Recently, Viatris has entered into a significant agreement to monetize its equity stake in Biocon Biologics Limited, aiming to bolster its operational portfolio. This strategic move underscores Viatris's commitment to innovating within the healthcare market while strategically managing its resources to enhance shareholder value.

Industry Overview in Malaysia

The pharmaceutical industry in Malaysia has experienced robust growth due to rising healthcare demands and a growing population. The increasing prevalence of chronic diseases, coupled with a h